相关实验视频
Updated: Jun 13, 2026
13:13
Biochemical Measurement of Neonatal Hypoxia
Published on: August 24, 2011
14.1K
血红蛋白,费里丁和乳酸脱酶作为新生儿败血症的预测标记物
Nicoleta Lungu1, Daniela-Eugenia Popescu2, Aniko Maria Manea1
1Department of Obstetrics-Gynecology and Neonatology, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
Journal of personalized medicine
|May 25, 2024
概括
乳酸脱酶 (LDH) 和费里水平是诊断新生儿败血症的有效生物标志物. 新生儿中这些标志物的水平升高可以帮助早期发现败血症,以便及时治疗.
科学领域:
- 新生儿医学 新生儿医学
- 生物标志物研究 生物标志物研究
- 传染性疾病 传染性疾病
背景情况:
- 新生儿败血症是一个重大的诊断挑战.
- 早期和准确的诊断对于有效的干预和改善结果至关重要.
- 现有的诊断方法需要通过可靠的预测标记来增强.
研究的目的:
- 评估特定生物标志物在诊断新生儿败血症中的预测效果.
- 评估血清费里和乳酸脱酶 (LDH) 在新生儿中的诊断能力.
- 为了确定可靠的指标,用于新生儿早期的败血症检测.
主要方法:
- 一项病例控制研究涉及86名新生儿 (51名患有败血症) 在2018年10月至2023年7月期间住院.
- 静脉血液样本分析完整血清,费里丁,血红蛋白,LDH和血液培养物.
- 败血症阳性和败血症阴性新生儿组之间的生物标志物水平的比较.
主要成果:
- 两组之间妊娠年龄,出生体重或APGAR分数没有显著差异.
- 在通过剖腹产产产生的新生儿中观察到更高的败血症发病率.
- 与对照人群相比,新生儿患有败血症的血清费里和LDH水平显著升高.
- 费里丁和LDH在新生儿败血症诊断方面表现出良好的分辨能力.
- 后勤回归证实了升高的费里和LDH与败血症可能性的相关性.
结论:
- 血清费里丁和LDH度被验证为新生儿败血症的预测生物标志物.
- 这些生物标志物显示出早期检测易感新生儿的潜力.
- 基于LDH和费里水平的干预措施的实施可能会改善患者的治疗结果.
相关概念视频
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...